ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
D0816C00025: A Phase 1, Open-label, Parallel Group Study to Investigate Olaparib Safety andTolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours
Protocol ID
D0816C00025
Disease (Sub Disease)
Solid Tumours
Diagnosis Stage
Relapsed/refractory
Location
NSW, WA
Sponsor
AstraZeneca
Trial Status
Open
Sites
Perth Children's Hospital
Sydney Children's Hospital
Study Type
Treatment
Phase
Phase 1
Age Eligibility
0 Years to 18 Years
International registry ID's
NCT04236414
Back to Registry
Study Title D0816C00025: A Phase 1 Open-label Parallel Group Study to Investigate Olaparib Safety andTolerability Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours
Protocol ID D0816C00025
Disease (Sub Disease) Solid Tumours
Diagnosis Stage Relapsed/refractory
Location NSW / WA
Sponsor AstraZeneca
Links https://clinicaltrials.gov/ct2/show/NCT04236414
Trial Status Open
Trial Open Date 01/11/2022
Sites Perth Children's Hospital / Sydney Children's Hospital
Study Type Treatment
Phase Phase 1
Age Eligibility 0 Years to 18 Years
International registry ID's NCT04236414

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168